We are live on ! Find out more
GSK icon

GSK
GSK

762 hedge funds and large institutions have $8.06B invested in GSK in 2016 Q4 according to their latest regulatory filings, with 110 funds opening new positions, 211 increasing their positions, 327 reducing their positions, and 80 closing their positions.

New
Increased
Maintained
Reduced
Closed

38% more first-time investments, than exits

New positions opened: 110 | Existing positions closed: 80

12% more call options, than puts

Call options by funds: $154M | Put options by funds: $137M

3% more funds holding

Funds holding: 740 → 762 (+22)

0.07% less ownership

Funds ownership: 3.47% → 3.41% (-0.07%)

12% less capital invested

Capital invested by funds: $9.13B → $8.06B (-$1.07B)

22% less funds holding in top 10

Funds holding in top 10: 9 → 7 (-2)

35% less repeat investments, than reductions

Existing positions increased: 211 | Existing positions reduced: 327

Holders
762
Holders Change
+22
Holders Change %
+2.97%
% of All Funds
19.05%
Holding in Top 10
7
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-22.22%
% of All Funds
0.17%
New
110
Increased
211
Reduced
327
Closed
80
Calls
$154M
Puts
$137M
Net Calls
+$16.3M
Net Calls Change
-$52.8M

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$91.1M
2
Two Sigma Advisers
Two Sigma Advisers
New York
+$90.1M
3
Renaissance Technologies
Renaissance Technologies
New York
+$85.2M
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$65.9M
5
Millennium Management
Millennium Management
New York
+$50.5M

Top Sellers

Rank Fund Capital Flow
1
Arrowstreet Capital
Arrowstreet Capital
Massachusetts
-$195M
2
JP Morgan Chase
JP Morgan Chase
New York
-$85.7M
3
Federated Hermes
Federated Hermes
Pennsylvania
-$73.9M
4
Macquarie Group
Macquarie Group
Australia
-$47.1M
5
Neuberger Berman Group
Neuberger Berman Group
New York
-$33.8M
Name Holding Trade Value Shares
Change 		Change in
Stake
CIM
201
Calvert Investment Management
Maryland
$2.43M -$204K -4,139 -8%
MA
202
MUFG Americas
New York
$2.42M -$3.16K -64 -0.1%
ISL
203
Ingalls & Snyder LLC
New York
$2.4M -$45.1K -912 -2%
CCM
204
Cullen Capital Management
New York
$2.38M -$134K -2,720 -5%
RG
205
Rikoon Group
New Mexico
$2.37M +$761K +15,413 +49%
SEC
206
Seven Eight Capital
New York
$2.32M +$2.38M +48,185 New
CLOS
207
Compagnie Lombard Odier SCmA
Switzerland
$2.31M +$356K +7,200 +18%
OPPM
208
Opus Point Partners Management
New York
$2.31M – – –
SWM
209
Stockman Wealth Management
Montana
$2.3M +$349K +7,059 +17%
FAM
210
Fred Alger Management
New York
$2.27M -$620K -12,542 -21%
MFS
211
MSI Financial Services
Massachusetts
$2.27M +$162K +3,289 +7%
PRS
212
Pinkerton Retirement Specialists
Idaho
$2.25M -$28.7K -580 -1%
MHC
213
Meyer Handelman Company
New York
$2.24M – – –
EA
214
Edge Advisors
Georgia
$2.22M +$2.28M +46,222 New
ICOA
215
Investment Centers of America
North Dakota
$2.22M +$1.98K +40 +0.1%
HFS
216
HL Financial Services
Kentucky
$2.21M -$186K -3,756 -8%
WMSA
217
Weiss Multi-Strategy Advisers
New York
$2.19M +$988K +20,000 +78%
HT
218
HAP Trading
New York
$2.17M +$1.3M +26,384 +141%
AL
219
AJO LP
Pennsylvania
$2.15M +$436K +8,828 +25%
HWM
220
Holloway Wealth Management
Florida
$2.11M – – –
NFA
221
Nuveen Fund Advisors
Illinois
$2.09M +$581K +11,753 +37%
BRWA
222
B. Riley Wealth Advisors
Florida
$2.03M -$118K -2,393 -5%
SCM
223
Stevens Capital Management
Pennsylvania
$1.98M +$1.77M +35,834 +671%
GG
224
Gofen & Glossberg
Illinois
$1.96M -$184K -3,734 -8%
Mirae Asset Global Investments
225
Mirae Asset Global Investments
South Korea
$1.95M +$3.46K +70 +0.2%
7 8
9
10 11

GSK Hedge Fund Activity: Q4 2016 in Review

762 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q4 2016, worth a combined $8.06B — down 12% from $9.13B a quarter earlier.

Buyers outnumbered sellers: 110 funds opened new GSK positions and 80 closed out — a net gain of 30 holders — while 211 added to existing stakes and 327 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $91.1M. The largest seller was Arrowstreet Capital, exiting entirely with an estimated $195M sold.

  • 762 institutional investors held GSK (GSK) as of Q4 2016, up from 740 in Q3 2016.
  • Funds reported $8.06B of GSK stock for Q4 2016, down 12% quarter-over-quarter.
  • 110 funds opened new GSK positions in Q4 2016 and 80 closed out, a net change of +30 holders.
  • The largest GSK buyer in Q4 2016 was T. Rowe Price Associates, an estimated $91.1M added.
  • The largest GSK seller in Q4 2016 was Arrowstreet Capital, an estimated $195M sold.

Based on aggregated 13F filings for Q4 2016.